ScholarIQanswers from OpenAlex & ORCID
William R. Wilcox
ResearcherPublications, citations & collaboration network
William R. Wilcox is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does William R. Wilcox have?
ScholarIQindexed works
William R. Wilcox has 560 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does William R. Wilcox have?
ScholarIQcitation count
William R. Wilcox has 23,287 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of William R. Wilcox?
ScholarIQh-index
William R. Wilcox has an h-index of 71 in OpenAlex.
What is the i10-index of William R. Wilcox?
ScholarIQi10-index
William R. Wilcox has an i10-index of 267 in OpenAlex.
What is the ORCID of William R. Wilcox?
ScholarIQorcid
The ORCID for William R. Wilcox is on the source record.
What is the OpenAlex record for William R. Wilcox?
ScholarIQopenalex
The OpenAlex for William R. Wilcox is on the source record.
What are the most-cited papers on William R. Wilcox?
ScholarIQmost cited works
Fabry disease revisited: Management and treatment recommendations for adult patients
Alberto Ortíz, Dominique P. Germain, Robert J. Desnick, Juan Politei, Michael Mauer, Alessandro P. Burlina, Christine M. Eng, Robert J. Hopkin, Dawn A. Laney, Aleš Linhart, Stephen Waldek, Eric Wallace, Frank Weidemann, William R. Wilcox
Agalsidase-Beta Therapy for Advanced Fabry Disease
Maryam Banikazemi, Jan Bultas, Stephen Waldek, William R. Wilcox, Chester B. Whitley, Marie McDonald, Richard S. Finkel, Seymour Packman, Daniel G. Bichet, David G. Warnock, Robert J. Desnick
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Dominique P. Germain, Derralynn Hughes, Kathy Nicholls, Daniel G. Bichet, Roberto Giugliani, William R. Wilcox, Claudio Feliciani, Suma P. Shankar, Fatih Süheyl Ezgü, Hernan Amartino, Drago Bratkovic, Ulla Feldt‐Rasmussen, Khan Nedd, Usama Sharaf El Din, Charles Marques Lourenço, Maryam Banikazemi, Joel Charrow, Majed Dasouki, David N. Finegold, Pilar Giraldo, Özlem Göker-Alpan, Nicola Longo, C. Ronald Scott, Roser Torrá, Ahmad Tuffaha, Ana Jovanović, Stephen Waldek, Seymour Packman, Elizabeth Ludington, Christopher Viereck, John Kirk, Julie Yu, Elfrida R. Benjamin, Franklin K. Johnson, David J. Lockhart, Nina Skuban, Jeff Castelli, Jay Barth, Carrolee Barlow, Raphael Schiffmann
Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry Disease
Dominique P. Germain, Stephen Waldek, Maryam Banikazemi, David A. Bushinsky, Joel Charrow, Robert J. Desnick, Philip Lee, Thomas Loew, Anouk C. Vedder, Rekha Abichandani, William R. Wilcox, Nathalie Guffon
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
Derralynn Hughes, Kathy Nicholls, Suma P. Shankar, Gere Sunder–Plassmann, David M. Koeller, Khan Nedd, Gerard Vockley, Takashi Hamazaki, Robin Lachmann, Toya Ohashi, Iacopo Olivotto, Norio Sakai, Patrick Deegan, David Dimmock, François Eyskens, Dominique P. Germain, Özlem Göker-Alpan, É. Hachulla, Ana Jovanović, Charles Marques Lourenço, Ichiei Narita, Mark Thomas, William R. Wilcox, Daniel G. Bichet, Raphael Schiffmann, Elizabeth Ludington, Christopher Viereck, John Kirk, Julie Yu, Franklin K. Johnson, Pol Boudes, Elfrida R. Benjamin, David J. Lockhart, Carrolee Barlow, Nina Skuban, Jeffrey P. Castelli, Jay Barth, Ulla Feldt‐Rasmussen